• Explore /
  • Poster
  • / A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Abstract Poster

Authors

null

Aaron James Scott

University of Colorado Denver, Aurora, CO

Aaron James Scott , Bert H. O'Neil , Wen Wee Ma , Steven J. Cohen , Dara Aisner , Alex R. Menter , Mohamedtaki Abdulaziz Tejani , Jonathan K. Cho , Peter Rubin , Andrew L. Coveler , Olugbenga Olanrele Olowokure , Joaquina Celebre Baranda , Mike Cusnir , Philip Agop Philip , Jeremiah Boles , Robert T. Maguire , Francois Wilhelm , Manoj Maniar , Christina Gomes , Wells A. Messersmith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01360853

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4117)

DOI

10.1200/jco.2015.33.15_suppl.4117

Abstract #

4117

Poster Bd #

228

Abstract Disclosures

Similar Posters

First Author: Aaron James Scott

First Author: Beate Schultheis

First Author: Andrew L. Coveler

First Author: Roland Lang